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1. Introduction
The liver is a common site of metastases. The most relevant metastatic tumor of the liver to
the surgeon is colorectal cancer because of the well-documented potential for long-term sur‐
vival after complete resection. However, a large number of other tumors commonly meta‐
stasize to the liver, including cancers of the upper gastrointestinal system (stomach,
pancreas, biliary), genitourinary system (renal, prostate), neuroendocrine system, breast, eye
(melanoma), skin (melanoma), soft tissue (retroperitoneal sarcoma), and gynecologic system
(ovarian, endometrial, cervix). [1]
The high frequency of liver metastases is caused by: [2]
1. The liver's vast blood supply, which originates from portal and systemic systems.
2. The fenestrations of the hepatic sinusoidal endothelium may facilitate penetration of
malignant cells into the hepatic parenchyma.
3. Humoral factors that promote cell growth and cellular factors, such as adhesion mole‐
cules, favor metastatic spread to the liver.
4. The liver's geographic proximity to other intra-abdominal organs may allow malignant
infiltration by direct extension.
© 2013 Abdeldayem et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Not so long ago, oncologists were so pessimistic about the appearance of hepatic metasta‐
ses  that  “no treatment”  was  often  the  recommendation.  Advancing technology and im‐
proved surgical techniques now offer potential therapeutic options for patients with such
lesions.  Patient  selection is  the  most  important  aspect  of  surgical  therapy for  metastatic
disease in the liver and clinical  follow-up of  resected patients  has identified those most
and least likely to benefit. Therefore, realistic expectations and honest patient education is
an important aspect of treatment. [1]
1.1. Clinical presentation
The clinical presentation of patients with liver metastases is variable and subtle. Most pa‐
tients are asymptomatic; a minority may report abdominal pain, jaundice, or pruritus. Hep‐
atic metastases from gastrointestinal carcinoid tumors are associated with release of
vasoactive peptides and serotonin into the systemic circulation. Symptoms of the carcinoid
syndrome, specifically flushing, sweats, and diarrhea, frequently occur in this setting. Liver
metastases from neuroendocrine tumors can lead to significant symptoms caused by the
production of functioning hormones. [1]
Physical examination may reveal hepatomegaly, a friction rub over hepatic metastases, or
ascites caused by hepatic venous obstruction or peritoneal carcinomatosis. [2]
1.2. Histopathology
The histologic appearances of metastatic deposits in the liver may resemble those of the pri‐
mary tumors; however, there can be marked differences. These differences exist because
metastatic foci are derived from a select subpopulation of tumor cells. Cells that are capable
of successful metastasis are believed to have specific characteristics, such as high motility,
resistance to immune-mediated destruction, and a high concentration of matrix receptors or
matrix-degrading enzymes.
Because the metastatic cell population may not be representative of the primary tumor, it
can be difficult to determine the site of origin based on the histologic appearance of the
metastases alone.
The  initial  light-microscopic  findings  can  be  used  to  categorize  the  tissue  into  one  of
three groups:
1. poorly differentiated carcinoma or adenocarcinoma,
2. well-differentiated adenocarcinoma, and
3. squamous carcinoma.
In most cases, immunohistochemical studies further differentiate these metastases. (Table 1) [3]
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Tumor Antigens
Colonic adenocarcinoma CEA
Pancreatic carcinoma CEA, pancreatic carcinoma-associated antigen
Lung carcinoma CEA, cytokeratin, neuron-specific enolase
Breast carcinoma CEA, milk-fat globulin, hCG
Thyroid carcinoma Thyroglobulin
Prostate carcinoma Prostate-specific acid phosphatase, PSA
Melanoma S-100, vimentin, neuron-specific enolase
Carcinoid Chromogranin, neuron-specific enolase
Lymphoma and leukemia CLA
Sarcoma
     Smooth muscle
     Skeletal muscle
     Neurogenic
     Cartilage
     Bone
Type IV collagen, vimentin, desmin
Myoglobin, vimentin, desmin
S-100, myelin basic protein
S-100, vimentin
Vimentin
Germ cell tumors α-fetoprotien, α1-antitrypsin
Trophoblastic tumors hCG, α-Fetoprotein
Table 1. Immunohistochemical antigens for the identification of primary tumors.
Abbreviations: CEA, carcinoembryonic antigen; CLA, common leukocyte antigen; hCG, hu‐
man chorionic gonadotropin; PSA, prostate-specific antigen.
1.3. Biochemical Laboratory Tests
The laboratory tests that are available for liver function assessment are not very sensitive.
CEA remains the most sensitive test for metastatic colon cancer, but even this test can be
normal in the presence of liver metastases, especially with minimal hepatic disease.
1.4. Imaging Techniques
The choice among the various techniques, and the sequence with which they are used,
should be guided primarily by the clinical indication, taking into account the primary type
and the different possible treatments, which also depend on the general status of clinical his‐
tory of the patient. Dedicated liver imaging is not needed in patients diagnosed with disse‐
minated, inoperable disease. [4]
1.4.1. Ultrasonography
1.4.1.1. Transabdominal ultrasonography (US)
US presents several advantages, including low cost, absence of irradiation, wide availability,
and portability. Transabdominal ultrasound generally has a lower sensitivity for tumor detec‐
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tion than does CT scan or MR imaging, especially for lesions less than 2 cm in size. US is most
commonly used for screening for metastases because of its wide availability. Hepatic metasta‐
ses may be hypoechoic, hyperechoic, cystic, or of mixed echogenicity on ultrasound. Hypere‐
choic masses are observed more commonly in vascular tumors, such as renal cell and islet cell
tumors. Hypovascular lesions, such as lymphoma, appear as hypoechoic masses. [5]
1.4.1.2. Contrast-enhanced US
Contrast-enhanced US, using intravascular microbubble contrast agents, has shown similar
accuracy compared to CT and MR. An advantage of contrast-enhanced US is the potential
for characterization of liver lesions based on morphologic evaluation as well as temporal
vascular enhancement pattern. During the portal venous phase, benign lesions typically en‐
hance more than the liver, whereas malignant lesions enhance less. [6]
1.4.1.3. Endoscopic ultrasound (EUS)
EUS is a well-established tool for diagnosing and staging various gastrointestinal tumors,
especially pancreatic cancer; however, it is not used often for hepatic imaging. A few reports
in the literature address the use of EUS in the evaluation of hepatic metastases. EUS can de‐
tect lesions that are not seen on conventional CT scanning and allows for tissue sampling
using fine-needle aspiration. [4]
Figure 1. Computed tomography of hypervascular liver metastases from a renal primary tumor at the arterial phase.
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1.4.1.4. Intraoperative US (IOUS)
IOUS involves a direct scan of the liver, allowing the use of higher-frequency transducers
with higher resolution. IOUS can also be useful at detecting small, deep hepatic metasta‐
ses not palpable.  IOUS is more accurate than conventional CT scanning or MR imaging
for delineating liver lesions and is regarded as an important tool in determining resecta‐
bility and prognosis. [7]
1.4.2. Computed Tomography
1.4.2.1. Noncontrast Computed Tomography
Contrast CT is sometimes not possible because of contrast allergic reactions or renal impair‐
ment. Although the sensitivity and specificity of noncontrast CT is far reduced as compared
to contrast CT, it may help in identifying hypervascular metastases (especially carcinoid tu‐
mors, islet cell tumors, and renal cell carcinomas) or visualizing calcifications or hemor‐
rhage. Noncontrast CT often fails to distinguish hypovascular tumors from the liver
parenchyma. Nonenhanced blood vessels may also appear as low-attenuation masses and
be confused with metastases. [4]
Figure 2. Computed tomography 3-D reconstruction before surgical showing liver metastases (http://c2i2.digithala‐
mus.com/winter2003/Imaging%20update%20in%20metastatic%20liver%20disease.asp).
1.4.2.2. Contrast Computed Tomography
The CT appearance of liver metastases varies according to the pathologic type of the pri‐
mary tumor. Most lesions are seen best in the portal venous phase, and some lesions are best
seen in delayed venous and occasionally arterial phases. Metastases from melanomas, sarco‐
mas, neuroendocrine tumors, and renal cell carcinomas (fig. 1) are hypervascular and there‐
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fore better visualized during the hepatic arterial phase. Metastases from colorectal cancer
are hypovascular and therefore better visualized during the portal venous phase. [8]
1.4.3. Magnetic Resonance Imaging (MRI)
T1-weighted images generally show hepatic metastases as low-intensity lesions, whereas
T2-weighted images show these lesions to be areas of increased signal intensity. Dynamic,
breath-hold MR imaging with a gadolinium-based contrast material is considered to be the
most sensitive MR technique for detection of hepatic metastases (fig. 3). Similar to CT, MR
angiography can be used as a noninvasive method to evaluate hepatic vasculature. Novel
MR contrast agents have the potential for improving detection of liver metastases. [8, 9]
1.4.4. Positron Emission Tomography (PET)
PET, in which a radioactively labeled tracer is administered to the patient and the scanner
collects the emitted positron radioactivity to generate an image, allows imaging of cellular
processes (such as cellular proliferation (18F-labeled thymidine), hypoxia (18F-labeled Mi‐
so), and blood flow ([15O]water) to be visualized. The majority of clinical experience relies
on the uptake and use of glucose in human cells. 18F-Fluorodeoxyglucose 18FDG, the most
commonly used marker in PET imaging, is an analogue of glucose in which a carbon atom is
replaced by a radioactive fluorine isotope. 18FDG is transported into cells, where it accumu‐
lates to create an intense signal on PET imaging. Malignant lesions typically have increased
18FDG uptake because of the increased expression of glucose transporter proteins and ele‐
vated levels of glycolysis. [10, 11]
Figure 3. Liver metastases after Mn DPPD or mangafodipir injection.
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1.4.5. PET/CT (fig. 4)
Despite excellent clinical results with FDG PET, the technique is intrinsically limited by the
lack of precise and reliable anatomic information. Foci of increased uptake that are clearly lo‐
cated in the liver parenchyma are readily identified and usually correspond to metastases, but
the bowel uptake is highly variable and may be focally increased in regions close to the liver,
and therefore be mistaken with peripheral liver lesions. Combined PET/CT scanners allow the
precise localization of the abnormal areas of uptake. Modern PET/CT devices are equipped
with high-end CT scanners, fully capable of performing full diagnostic CT studies. [11]
2. Colorectal Liver Metastases (CLM)
The liver is the most common site for hematogenous metastasis from colorectal cancers
(CRC). A quarter of patients with primary colorectal carcinoma are found to have synchro‐
nous hepatic metastasis. Nearly half of patients who undergo resection of the colorectal pri‐
mary eventually develop metachronous liver metastasis. [2]
CRC principally spreads through two mechanisms:
1. Via portal venous drainage.
2. To regional lymph nodes and then through central lymphatics into the systemic cir‐
culation or
2.1. Prognostic Variables and Staging Systems
All patients with colorectal metastases by definition are grouped as stage IV in the TNM
staging system, but considerable diversity exists within this group. The prognosis of a pa‐
Figure 4. PET/CT Cancer pancreas with liver metastases (http://www.radrounds.com/photo/petct- -2context).
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tient with a solitary liver metastasis found years after resection of a node-negative right co‐
lon cancer is different from the prognosis of a patient with synchronously discovered diffuse
bilateral liver metastases at the time of operation for a perforated node- positive colon can‐
cer. A classification system that can discriminate between these patients and provide mean‐
ingful prognostic information is essential. This classification system must enable the
comparison of patients from diverse publications and facilitate patient selection for adjuvant
therapy or clinical trials. [2, 12]
2.1.1. Independent predictors of prognosis include [2]
1. the presence of extrahepatic disease,
2. a positive resection margin,
3. nodal metastases from primary cancer,
4. a short disease-free interval,
5. largest tumor greater than 5 cm,
6. more than one liver metastasis, and
7. CEA greater than 200 ng/mL.
• The first two parameters are data that are determined intraoperatively only because preop‐
erative evidence of extrahepatic disease and inability to obtain negative margins would be
relative contraindications to surgery. There is no role for surgical debulking in this setting.
• Using the last five criteria, a preoperative clinical risk score (CRS) system was created
with each positive criterion counting as 1 point.
• This CRS is a simple, easily remembered staging system for classifying patients with liv‐
er-exclusive metastatic colorectal cancer
2.1.2. Prognostic Scoring System for Hepatic Colorectal Metastases: Clinical risk score (CRS)
• Node-positive primary tumor
• Disease-free interval <12 mo between colon resection and appearance of metastases
• Size of largest lesion >5 cm
• >1 tumor
• CEA >200 ng/dL
Sum of points with 1 point assigned for each positive criterion
• The presence of any one of these characteristics still was associated with a 5-year survival.
• No single criterion can be considered a contraindication to resection.
• The total score out of 5 is highly predictive of outcome.
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• A score of 2 or less places a patient in a good prognostic group, for whom resection is ideal.
• For scores of 3 or 4, outcome is less favorable, and patients should be considered for ag‐
gressive trials of adjuvant therapy.
• For a score of 5, long-term disease-free survivors rarely are encountered, and resections in
this high-risk group should be accompanied by trials of adjuvant therapy.
• This CRS proved useful in selection of patients for neoadjuvant therapy and ablative
therapies and in stratification of patients enrolled in clinical trials
• A high CRS has been associated with sufficiently high incidence of occult metastatic dis‐
ease that fluorodeoxyglucose positron emission tomography (FDG PET) can be justified
as a preoperative test
• The yield from laparoscopy in the preoperative staging of patients with hepatic colorectal
metastases also has been correlated with the CRS.
• For patients with a high CRS, a laparoscopy can save patients with disseminated disease
from having a laparotomy, minimizing morbidity and hospital stay, whereas patients
with a low CRS can avoid the added anesthesia and operating room time associated with
a negative laparoscopy. [2, 12]
2.1.3. Molecular Determinants of Outcome
There are reports that molecular characteristics that predict response to chemotherapy, such
as tumor thymidylate synthase levels or levels of the transcription factor E2F-1, are impor‐
tant in predicting the outcome It is likely that these and other molecular determinants will
be incorporated into postoperative prognostic scales in the future. [2]
2.2. Medical Treatment
Over the past 3 decades, the most widely used chemotherapeutic agent in the treatment
of  metastatic  CRC  has  been  5-fluorouracil  (5-FU),  used  either  alone  or  in  combination
with other chemotherapies. [13]
Now, the most commonly used regimens are: FOLFOX, FOLFIRI, and FOLFOXIRI.
2.2.1. FOLFOX is a made up of the drugs
• FOL – Folinic acid (leucovorin), a vitamin B derivative used as a "rescue" drug for high
doses of the drug methotrexate and that modulates/potentiates/reduces the side effects
of fluorouracil;
• F – Fluorouracil (5-FU) fluorouracil (5-FU), a pyrimidine analog and antimetabolite which
incorporates into the DNA molecule and stops synthesis; and
• OX – Oxaliplatin (Eloxatin) A platinum-based drug, usually classified as alkylating
agents, although it is not actually alkylating groups (functions by a similar mechanism)
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This regimen is recommended for 12 cycles, every 2 weeks. The recommended dose sched‐
ule given every two weeks is as follows:
• Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL D5W and leucovorin 200 mg/m²
IV infusion in D5W both given over 120 minutes at the same time in separate bags using a
Y-line, followed by 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by 5-FU
600 mg/m² IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion.
• Day 2: Leucovorin 200 mg/m² IV infusion over 120 minutes, followed by 5-FU 400 mg/m²
IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m² IV infusion in 500 mL D5W
(recommended) as a 22-hour continuous infusion.FOLFOX4 regime.
Premedication with antiemetics, including 5-HT3 blockers with or without dexamethasone,
is recommended.
FOLFOX4
drug dose administration time term
Oxaliplatin 85 mg/m² IV infusion 2 h day 1
Folinic acid 200 mg/m² IV infusion 2 h day 1 + 2
Fluorouracil 400 mg/m² IV bolus 2 min day 1 + 2
Fluorouracil 600 mg/m² IV infusion 22 h day 1 + 2
Table 2.
2.2.2. FOLFIRI is is made up of the following drugs:
• FOL – folinic acid (leucovorin).
• F – fluorouracil (5-FU); and
• IRI – irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from un‐
coiling and duplicating.
The dosage consists of: Irinotecan (180 mg/m² IV over 90 minutes) concurrently with folinic
acid (400 mg/m² [or 2 x 250 mg/m²] IV over 120 minutes).
Followed by fluorouracil (400-500 mg/m² IV bolus) then fluorouracil (2400-3000 mg/m² intra‐
venous infusion over 46 hours).
This cycle is typically repeated every two weeks. The dosages shown above may vary from
cycle to cycle.
FOLFOX and FOLFIRI are widely considered to be equivelent in the metastatic setting and
are generally selected according to the toxicity profile. The FOLFOX regimen is character‐
ized by a higher rate of grade 3 and 4 neurotoxicity and neutropenia. The FOLFIRI is associ‐
ated with more nasuea and vomiting, mucositis, and alopecia.
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2.2.3. Folfoxiri
• irinotecan, oxaliplatin, fluorouracil, and folinate
FOLFOXIRI has been shown to have better results than FOLFIRI and FOLFOX in sever‐
al studies.
2.2.4. Cetuximab (Erbitux) and panitumumab (Vectibix)
Both are monoclonal antibodies against the epidermal growth factor receptor (EGFR) and
are now an important part of the treatment algorithm for unresectable colorectal metastases.
Cetuximab is a chimeric monoclonal antibody approved for treatment of metastatic CRC in
combination with irinotecan in patients with disease refractory to irinotecan or as a single
agent in patients who cannot tolerate irinotecan or oxaliplatin. Panitumumab is a fully
humanized monoclonal antibody and therefore appears to have a lower rate of serious infu‐
sion reactions compared with cetuximab. Like cetuximab, panitumumab is approved for sin‐
gle-agent therapy in patients who have progressed on standard chemotherapy. [2]
2.3. Regional treatment for metastatic colorectal cancer
The rationale for a regional approach to what normally would be thought of as a systemic proc‐
ess is based on the concept that tumor cells from gastrointestinal malignancies, especially col‐
orectal cancer, spread hematogenously via the portal circulation, making the liver the first site
of metastasis in most patients. This stepwise spread of cancer from primary site to liver and
from there to other organs provides an opportunity to prevent dissemination of tumor to other
sites by direct treatment of hepatic metastases. In this way, metastatic colorectal cancer differs
from most other metastatic malignancies. In addition, the remarkable ability of the liver to re‐
generate after hepatic resection has enabled aggressive surgical options for hepatic metastases.
There is no doubt that surgery alone can cure a subset of patients. [14]
Liver resection has become the standard treatment for metastatic lesions from colorectal pri‐
maries. With many series reporting long-term survival for these patients, even before the era
of modern chemotherapy, 5-year, 10-year, and 20-year survivals with hepatic resection can
be expected to reach 40%, 25%, and 20%. [2]
2.3.1. Preoperative evaluation
All patients with CLM benefit from evaluation by a multidisciplinary team comprising
physicians (surgeons, medical oncologists, radiologists, pathologists), nurses, social work‐
ers, and research coordinators. The central tenets in the preoperative evaluation of patients
for potential surgical resection of CLM are:
1. establishing the diagnosis,
2. anatomically defining the liver lesion for diagnosis and surgical planning, and
3. staging to rule out extrahepatic disease.
4. evaluation of the patient's fitness for operation;
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5. estimation of an individual's tumor biology.
Preoperative biopsy of CLM is rarely indicated or beneficial for assessment of CLM, and has
been associated with tumor dissemination and decreased survival. Preoperative biopsy may
have usefulness for confirmation of extrahepatic disease when a change in therapy is plan‐
ned based on the biopsy results. [1]
2.3.1.1. Evaluation of Fitness for Operation
A careful evaluation of a patient's physiologic capability to tolerate hepatic resection is neces‐
sary to ensure favorable outcomes after hepatectomy. History, physical examination, and rou‐
tine laboratory studies (complete blood count, liver function testing, and coagulation studies)
are relied on to screen for underlying liver dysfunction.The criteria for patient operability are
similar to the criteria considered for any major laparotomy. A history of cardiac and pulmona‐
ry disease must be investigated because these patients are at significant risk for perioperative
complications. Any previous liver disease that might have impaired hepatic function should
be evaluated because this determines the volume of liver than can be resected safely. [2, 14]
2.3.1.2. Anatomic and Functional parameters
Determination of resectability is primarily based on preoperative imaging. High-quality cross-
sectional imaging is critical for gauging the extent of disease, response to preoperative thera‐
py, and for operative planning (The role of preoperative imaging was discussed above). [14]
Patients should be routinely reimaged after any course of systemic therapy; preferably with‐
in 4 weeks of planned resection. Meticulous preoperative attention to the relationships of
CLM to arterioportal inflow, biliary drainage, and hepatic venous outflow is necessary and
allows for an informed and efficient hepatectomy. Preoperative imaging may also help to
identify the presence of concomitant parenchymal disease (eg, fibrosis/cirrhosis, portal hy‐
pertension, steatohepatitis) or extrahepatic disease. [2]
Resectability of CLM has been well defined by the American Hepato-Pancreato-Biliary As‐
sociation (AHPBA)/Society of Surgery of the Alimentary Tract (SSAT)/Society of Surgical
Oncology (SSO) in a 2006 consensus statement as an expected margin-negative (R-0) resec‐
tion resulting in preservation of at least 2 contiguous hepatic segments with adequate in‐
flow, outflow, and biliary drainage with a functional liver remnant (FLR) volume of more
than 20% (for healthy liver). [1, 14]
2.3.1.3. Tumor biology
Careful evaluation of all patients in a multidisciplinary setting allows for better identifica‐
tion of those patients most likely to benefit from surgical resection as opposed to those who
would benefit more from nonoperative therapies, given their particularly aggressive dis‐
ease. Consideration of this question is far from an exact science, but valuable information
can be gleaned from factors such as [1]
1. the stage of primary disease,
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2. number and distribution of CLM,
3. tumor histology,
4. response to chemotherapy,
5. rate of growth of CLM on serial imaging,
6. rate of increase in serum carcinoembryonic antigen (CEA).
2.3.1.4. Diagnostic laparoscopy
Diagnostic laparoscopy has a role in staging those patients in whom preoperative imaging
or high-risk scores suggest a high likelihood for finding intra-abdominal extrahepatic dis‐
ease or for patients with indeterminate intrahepatic lesions that may be best characterized
by IOUS. Laparoscopy is useful at identifying peritoneal disease or the involvement of peri‐
portal lymph nodes not apparent on preoperative imaging. When laparoscopy is employed,
laparotomy can be avoided in patients with unresectable disease. [1, 2]
2.3.2. Operative technique
The goal should be a safe R-0 hepatectomy allowing for preservation of adequate FLR vol‐
ume to avoid hepatic insufficiency. Given the significant decrease in survival between R-0
and R-1/2 resections, the ability to achieve R-0 resection, is paramount. The optimal width of
resection margin is unclear, with no clear minimum margin established. A predicted margin
width of less than 1 cm should not be used as an exclusion to resection. The extent of resec‐
tion depends on the number and location of metastases relative to the portal triads and hep‐
atic veins. Anatomic resections, which are facilitated by intraoperative ultrasound, are
preferred to wedge resections. Anatomic resections permit excision of parenchymal areas
distal to the tumor, where vascular micrometastases tend to occur, and, most importantly
they are less likely to have positive margins. [14, 15]
The principles of hepatic resection are no different for colorectal metastases than for any
other hepatic surgery. Technical details of liver mobilization and various anatomic hepatec‐
tomies have been well described elsewhere in this book. Most procedures can be divided in‐
to distinct stages: [1, 2, 14, 15]
1. exploration,
2. liver mobilization,
3. intraoperative ultrasonography,
4. inflow control,
5. outflow control,
6. parenchymal transection, and
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7. hemo- and biliostasis.
The abdomen must be explored thoroughly for evidence of extrahepatic metastases. In par‐
ticular, the celiac axis and portocaval and hilar lymph nodes must be palpated, and any sus‐
picious nodes should be removed and examined by frozen section.
Most surgeons routinely use intraoperative ultrasound after mobilization of the liver. IOUS
can delineate better the interior anatomy of the liver, including intrahepatic vessels, and hepat‐
ic resection can be performed more safely and in a more anatomically oriented fashion. In ad‐
dition to the initial planning, the operation can be monitored by the repeated use of IOUS
because the resection line is displayed in relation to the lesion and blood vessels. [14, 15]
2.3.3. Follow-up
Patients after hepatic resection usually are monitored in an attempt to identify early recur‐
rence that may be amenable to further resection. Currently, most patients undergo serial
physical examination, serum CEA level, annual chest x-ray, and CT of the abdomen and pel‐
vis every 3 to 4 months for the first 2 years and then every 6 months for the next 5 years. [16]
2.3.3.1. Adjuvant Chemotherapy
1- Adjuvant Systemic Chemotherapy
Although the use of oxaliplatin-based or irinotecan-based chemotherapies in this setting is
common, there are no clear data from comparative studies supporting such practice. [17]
2- Adjuvant Hepatic Arterial Infusion Chemotherapy
Regional chemotherapy, via the hepatic artery, is a theoretically attractive mode of adjuvant
therapy, because the liver is the most common site for tumor recurrence after liver resection
and is the sole site of recurrence in 40% of patients.
The rationale for HAI of chemotherapy is based on the concept that most metastatic liver
tumors preferentially derive their blood supply from the hepatic artery, whereas normal
hepatic tissue relies on the portal venous blood supply.
The ability of the hepatic parenchyma to extract and metabolize chemotherapy drugs to
nontoxic metabolites offers a unique opportunity to administer highly toxic drug levels to
tumor cells, while minimizing systemic toxicity. The most extensively studied agent is 5-flu‐
orouracil-2-deoxyuridine (FUDR), an analogue of 5-FU that can be concentrated 100-fold to
400-fold in the liver because of a 95% hepatic extraction ratio. [17, 18, 19, 20]
2.4. Controversial issues
2.4.1. Downstaging of unresectable tumor and neoadjuvant chemotherapy.
Potential benefits of prehepatectomy chemotherapy include [2, 20]
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1. the potential to render formerly unresectable patients resectable i.e. the possibility for
downstaging liver metastases,
2. in vivo testing of chemotherapeutic efficacy,
3. identification of occult intra- or extrahepatic metastases, and
4. early exposure of subclinical microscopic metastases to systemic therapy.
5. with  prudent  monitoring  and  attention  to  comorbidities,  allows  for  improved  pa‐
tient selection
Patients with tumor progression during preoperative chemotherapy have a significantly
worse outcome CLM. Potential downsides of preoperative chemotherapy are largely related
to hepatic toxicities that may be clinically relevant. Oxaliplatin has been linked to steatohe‐
patitis and sinusoidal obstruction; irinotecan has been associated with steatohepatitis and
periportal inflammation. A preoperatively treated liver is more fibrotic, often with perivas‐
cular adhesions. The planes of resection are difficult to dissect, making the procedure more
challenging overall. Despite the operative complexity, the perioperative morbidity and mor‐
tality in the trials of resection after neoadjuvant chemotherapy do not seem to be higher
than series of de novo hepatic resection. [1, 2]
One controversial issue is the treatment of a patient with a complete clinical response to neoad‐
juvant chemotherapy. When there is no visible tumor left to resect, should a blind resection,
based on the site of previous metastasis, be undertaken? Suggested practice is to use intrao‐
perative ultrasound to attempt to identify the lesion, and if this is not possible a hepatic re‐
section of the area previously involved with tumor is performed. This is not, however, a
universally accepted practice. [1, 2, 20]
Patients who present with liver lesions that are potentially resectable for cure should be of‐
fered a surgical resection because there are no definite data supporting a neoadjuvant che‐
motherapeutic approach.
2.4.2. Repeated resection for recurrent tumor
In the absence of extrahepatic disease and in a patient with a good performance status and
adequate hepatic reserve, a repeat hepatectomy may be considered. Approximately one
third of recurrence is amenable to further resection The presence of adhesions and the al‐
tered anatomy of the liver, particularly the position of the vasculature and biliary system,
make this technically challenging.
There is a higher likelihood of further recurrence, however, and the study of adjuvant thera‐
py should be encouraged in these patients. [21]
2.4.3. Synchronous Metastases
Synchronous CLM are noted in 20% to 30% of patients at the time of initial colorectal cancer
diagnosis. Surgical management of this group of early metastases has been debated in terms
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of disease biology, operative approach (staged vs. simultaneous colorectal and liver resec‐
tion), the order of resection, and timing of chemotherapy. [2, 22]
Some suggests that synchronous diagnosis of metastases portends a worse prognosis, per‐
haps as a result of a failure to detect micrometastatic foci in the liver. Delaying hepatic resec‐
tion may increase survival in the surgically resected group by selecting out the patients with
aggressive tumor biology who would be unlikely to derive a survival benefit from resection.
Although delayed resection does not seem to impair survival, it does increase the volume of
resected liver, a factor that is predictive of postoperative complications. [22]
Potential benefits of simultaneous CLM resection include [2]
1. avoidance of morbidity of a second laparotomy and anesthesia, and
2. decreased time to initiation of chemotherapy.
Risks of simultaneous resection are related to the magnitude and complexity of the com‐
bined operation.
A selective approach to synchronous CLM should be based on careful consideration of the
technical complexity and risks for the colorectal and liver resections, as well as judicious in‐
traoperative decision making. Good judgment is required in selection of patients for a simul‐
taneous or a staged resection in close coordination with medical oncologists and
collaborating surgeons. [1]
2.4.4. Bilobar Metastases
Bilobar  metastases  are  no  longer  an  absolute  contraindication  to  resection.  Possible  op‐
tions include:
1. Extended hepatectomy,
2. 2-stage hepatectomy,
3. Combined hepatic resection and ablation.
4. For patients with insufficient FLR, portal vein embolization (PVE) may be a useful ad‐
junct to increase the size of the FLR and allow for safe extended hepatectomy.
Two-stage hepatectomy for patients with bilobar metastases involves an initial hepatectomy
with contralateral portal vein ligation or postoperative PVE, followed by chemotherapy. Af‐
ter restaging, a second hepatectomy is performed based on response to PVE/chemotherapy
and ability to achieve resection with an adequate FLR. A proportion of patients will not be
eligible for second hepatectomy because of disease progression, inadequate FLR, or perio‐
perative or chemotherapy-associated complications. [23, 24]
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2.4.5. Extrahepatic Colorectal Metastases
In the past, extrahepatic disease has been labeled an absolute contraindication to resection of
CLM. However, with the advent of more effective systemic therapies, a growing body of lit‐
erature supports R-0 resection of CLM and extrahepatic metastases. [25]
• An assessment of tumor biology is critical to selecting patients for resection of CLM as
well as extrahepatic metastases. For patients found to have extrahepatic metastases pre‐
operatively, a short course of preoperative chemotherapy followed by reimaging is pru‐
dent to better define the disease biology.
• Intraoperative decision for previously unrecognized intra-abdominal extrahepatic meta‐
stases is difficult. The following should be considered:
1. the complexity and extent of the R-0 hepatic resection,
2. the complexity of resection of the R-0 extrahepatic metastases,
3. the physiologic age of the patient,
4. availability of postoperative chemotherapeutic options, and
5. the  patient's  risk  of  rapid  progression  with  the  additional  finding  of  extrahepatic
metastases.
3. Neuroendocrine Liver Metastases (NLMs)
The liver is the most common site of metastatic disease for neuroendocrine tumors. Nonop‐
erative therapies for advanced neuroendocrine malignancies are associated with minimal re‐
sponse rates, short durations of disease stability, and no clear survival benefit. [26]
3.1. Pathology and Classification
Most NLMs are of gastrointestinal or pancreatic origin, or so-called gastroenteropancreatic
(GEP) tumors GEP neuroendocrine tumors historically are divided into two broad types:
carcinoid and noncarcinoid. Either type may or may not be associated with hormone pro‐
duction causing a clinical endocrinopathy (functional or nonfunctional). [26, 27]
Traditionally, gastrointestinal carcinoids have been classified by their site of origin—foregut
(lung, thymus, stomach, duodenum, pancreas, bile duct, gallbladder, and liver), midgut
(small intestine, appendix, and proximal colon), and hindgut (distal colon and rectum)—be‐
cause of the various biologic and biochemical features shown within these groups. Pancreat‐
ic neuroendocrine tumors have been classified by whether they are functional or not. [26, 28]
Regardless of origin, neuroendocrine tumors are similar histopathologically. Many histolog‐
ic and morphologic features may be shared by benign and malignant tumors. Histologically,
neuroendocrine tumors typically are well differentiated, and atypia and mitoses are rare.
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Neuroendocrine tumors stain positive for chromogranin A, neuron-specific enolase, and
synaptophysin, which confirms neuroendocrine cell origin. Neuroendocrine tumors also
stain positively for one or more endocrine hormones immunohistochemically. [27]
Morphologically, neuroendocrine tumors can be solitary or multiple and solid or cystic. Tu‐
mor size alone is not a reliable indicator of malignancy. Neuroendocrine tumors greater than 2
cm throughout the GEP tract have a greater probability of malignant behavior, however, than
tumors less than 2 cm. Gross or microscopic vascular invasion may occur for any GEP neuroen‐
docrine tumors, although major vascular invasion is most typical of pancreatic NECs. Only the
confirmed presence of metastases confers an unequivocal diagnosis of malignancy. [28]
Regardless of whether NECs are classified as carcinoid or noncarcinoid, the natural history
of patients with unresected or unresectable hepatic metastases generally has been similar.
Overall, patients with unresected hepatic metastases from NEC have an approximately 30%
5-year survival The presence of liver metastases alone is the most significant factor adverse‐
ly affecting outcome Five-year survival with and without liver metastases from NECs is ap‐
proximately 30% to 40% and 90% to 100%. [26]
3.2. Treatment of NLMs
3.2.1. Liver resection
The treatment of hepatic metastases from NECs is aimed at reduction of the mass of malig‐
nant tissue (cytoreduction) chiefly for two reasons. [29]
First, metastatic gastrointestinal neuroendocrine tumors are usually indolent and slow
growing because most are low-grade malignancies (WHO classification). Chemotherapeutic
and radiotherapeutic regimens targeted at rapidly dividing cells are relatively ineffective,
targeting only a paucity of the total population of malignant cells.
Second, symptoms secondary to expression and secretion of biologically active peptides by
these tumors are directly related to overall mass of tumor, although production of peptides
may be heterogeneous among individual metastases. Similarly, pain and debilitating de‐
crease in performance status may have a negative impact on quality of life for nonfunctional
NECs metastatic to the liver. Cytoreduction of the tumor is the most direct and immediately
effective method to provide symptomatic relief.
These reasons, coupled with improved safety for hepatic resection, have prompted hepatic
resection as a primary therapeutic option for patients with functional and nonfunctional
metastatic GEP NECs. Currently, hepatic resection of NLMs is recommended if the primary
tumor and regional disease are resectable or resected, and greater than 90% of hepatic meta‐
stases are resectable or ablatable.
The concept  of  hepatic  resection for  NLMs has grown because of  several  clinical  obser‐
vations: [30]
1. the protracted natural history of NECs compared with other gastrointestinal tract cancers,
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2. the often prolonged duration of intrahepatic disease before evidence of extrahepatic
progression,
3. the clinical impression that the severity of clinical endocrinopathies correlates with the
intrahepatic volume of metastatic disease,
4. the frequent resectability of the primary and regional neuroendocrine tumors despite
metastatic disease, and
5. the rarity of underlying concomitant hepatic disease (fibrosis or cirrhosis).
3.2.1.1. Debulking strategy
When complete resection of gross liver disease is not feasible or in the presence of unresecta‐
ble extrahepatic disease, resection as a tumor debulking strategy should be considered in
patients with extreme hormonal symptoms refractory to other treatments or with tumors in
locations that would affect short-term quality of life, such as large lesions abutting the hep‐
atic hilum (resulting in biliary obstruction) or the colon/duodenum (resulting in gastrointes‐
tinal obstruction). [31, 32]
3.2.1.2. Subsequent plan for treatment of recurrence. [26, 33]
1. For solitary recurrences, either resection or ablation is appropriate. Percutaneous abla‐
tive approaches often are preferable.
2. Repeat  hepatic  resection  is  advised  for  lesions  in  sites  that  preclude  safe  radiofre‐
quency ablation (RFA) (i.e.,  surface metastases adjacent to bowel, near bile ducts, or
near diaphragm).
3. Sequential ablation or resection is undertaken as recurrence is recognized until preclud‐
ed by extent of recurrence within the liver.
4. Extensive recurrent intrahepatic metastases are treated by embolization or chemoembo‐
lization with or without systemic chemotherapy in the absence of extrahepatic disease
and chemotherapy in the presence of extrahepatic disease.
3.2.2. Liver transplantation
Liver  transplantation  (OLT)  has  been  employed  increasingly  to  treat  metastatic  NEC.
OLT  may  be  indicated  if  the  primary  and  regional  NEC  has  been  resected,  and  distal
metastases  have  been  excluded.  While  transplantation  has  the  benefits  of  removing  all
hepatic  disease  burden,  rapid  disease  recurrence  is  near  universal.  Long-term  actuarial
survival  among  patients  transplanted  for  NLM  is  poor  compared  with  overall  patient
and  graft  survival  rates  for  all  indications.  At  present,  liver  transplantation  cannot  be
considered a viable option for unresectable NLM. OLT should be considered as an inves‐
tigative treatment alternative in specialty centers. [34]
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3.2.3. Radiofrequency Ablation
Radiofrequency ablation (RFA) can provide local control and short-term symptomatic relief
from NLM when resection is not possible. Successful ablation typically occur in the treat‐
ment of small metastases (<5 cm). [35-38]
3.2.4. Ethanol Ablation
Percutaneous ethanol injection permits ablation of metastases located adjacent to structures at
risk of damage by RFA. It can be performed on metastases located adjacent to vital structures
(e.g., the hepatic flexure of the colon); adjacent to large vessels vulnerable to the heat-sink ef‐
fect; and adjacent to central bile ducts, where subsequent biliary stricture may occur. [61]
3.2.4.1. Guidelines for Ablation
General guidelines in the ablation of liver metastases are analogous to the treatment of hep‐
atocellular carcinoma and colorectal metastases. [35-38]
There are three clinical scenarios for ablation of neuroendocrine hepatic metastases:
1. adjunct to concurrent surgical resection of hepatic metastases,
2. treatment of limited hepatic metastases in patients unfit for operation, and
3. primary  therapy  when  clinical  expertise  or  intraoperative  circumstances  preclude
safe resection.
3.2.5. Hepatic arterial therapy
Because neuroendocrine tumors usually are highly vascular lesions that predominantly de‐
rive blood supply from the hepatic artery (as opposed to the normal hepatic parenchyma
that derive the majority of blood supply from the portal vein), opportunities exist for select‐
ed ischemia of NLM and/or delivery of directed chemotherapy via hepatic artery therapy.
Hepatic arterial embolization with cyanoacrylate, gel foam particles, polyvinyl alcohol, and
microspheres have all been used to achieve distal embolization without surgical ligation of
the hepatic artery. Chemoembolization provides an intratumoral concentration of chemo‐
therapy that is 10 to 20 times higher than systemic administration.
Complete response and long-term survival are not common after hepatic arterial therapy, as
the periphery of the tumor is spared from ischemia or chemotherapy. Thus, embolization of
lesions close to the hepatic hilum is generally unsuccessful, as the periphery of the tumor
will still cause mass-effect associated symptoms. [39, 40]
The  morbidity  of  embolization  approaches  include  liver  abscess,  transient  liver  failure,
pleural effusion, and postembolization syndrome, the latter consisting of fever, abdominal
pain,  leukocytosis,  and  a  transient  increase  in  liver  enzymes  and/or  bilirubin.  Multiple
sessions of therapy are often needed with varying intervals between sessions. Contraindi‐
cations to hepatic arterial therapy include hepatic failure, portal vein occlusion, uncorrect‐
able coagulopathy, and renal failure. [40]
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3.2.6. Medical treatment
A- Somatostatin Analogues
Short-acting somatostatin analogue therapy is used to prevent or to treat the carcinoid crisis
periprocedurally for any intervention, including resection, transplantation, ablation, or em‐
bolization. Somatostatin analogue treatment generally is well tolerated. Steatorrhea, diar‐
rhea, abdominal discomfort, and biliary sludge or gallstones can develop, but rarely
preclude continued use. [41]
B- Chemotherapy
Systemic chemotherapy generally is reserved for patients with advanced or progressive dis‐
ease in whom other treatment efforts have failed Streptozocin-based combinations with 5-
FU and doxorubicin have resulted in objective responses. Carcinoid tumors may be less
sensitive to cytotoxic agents because of the preponderance of low-grade malignant (well-dif‐
ferentiated) histology and low proliferation index. [24]
C- Interferon Alfa
Systemic interferon alfa may be used to treat advanced NEC. The mechanism of interferon
alfa is mediated through direct inhibitors of the cell cycle (G1/S phase) and of protein and
hormone production, through antiangiogenesis, and indirectly through increased immune
stimulation. Adverse reactions to interferon alfa are common. Chronic fatigue and hemato‐
logic cytopenias are the most common side effects. [42]
3.3. Primary hepatic neuroendocrine tumors
NECs may arise primarily within the liver. The diagnosis presumes a thorough search and
exclusion of an extrahepatic NEC. The cell of origin is unknown. Pancreatic heterotopia has
been postulated as a source of these tumors. Some tumors may arise from intrahepatic bili‐
ary tract radicles because carcinoids of the extrahepatic biliary tract are more common. Pri‐
mary hepatic neuroendocrine tumors may be metastases from an occult primary NEC or a
primary NEC that had spontaneously regressed. [24]
4. Non-colorectal Non-neuroendocrine Liver Metastases (NCNNLM)
Except for gastrointestinal primaries, the liver is not the primary filter for venous blood. In
other words, liver metastases from nongastrointestinal cancers indicate systemic tumor
spread; this makes selection of patients a crucial factor to offer hepatic resection to patients
who may benefit the most.
Tumor biologies  among NCNNLM vary widely,  and their  treatment  requires  dedicated
multidisciplinary teams with expertise in diverse areas including hepatic surgery, surgical
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oncology,  medical  oncology,  radiation  oncology,  diagnostic  imaging,  and  interventional
radiology. Patient care must be individualized, especially in the absence of data to clearly
guide therapy. [43]
4.1. Treatment options
4.1.1. Resectional treatment
The potential utility of surgery in NCNNLM relates to several factors:
1. advances in chemotherapy have led to effective control of extra hepatic disease for cer‐
tain tumor types, supporting a rationale for surgical resection of LM in the presence of
presumed or de facto systemic disease;
2. improvements in patient preparation for surgery, surgical technique and perioperative
care have reduced the perioperative risk of hepatic resection, tipping the risk–benefit
ratio in favor of surgical resection in selected cases;
3. the increased emphasis on multimodality treatment approaches has improved patient
selection and strengthened the role of hepatic resection as a key component of integrat‐
ed multidisciplinary care in selected patients with NCNNLM.
Although it might appear that patients with isolated liver metastases can benefit from hepat‐
ic resection, the proper selection of patients that may potentially benefit from treatment re‐
mains the most critical issue. Patient selection criteria depend on the primary tumor type.
After selection based on patient performance status and evaluation of comorbidities, staging
studies are required not only to assess the overall disease status of the patient but also to
characterize liver lesions and their precise location relative to intrahepatic vascular struc‐
tures. Assessment of the liver volume that will remain after resection is an equally impor‐
tant component of surgical planning for extensive hepatectomy. [43, 45]
Patient selection and oncologic outcome of metastasectomy depends fundamentally on com‐
plete resection of all disease. Preoperative studies are essential in defining both the extent
and the limits of surgical resection. Hepatic volumetry to assess the planned future liver
remnant (FLR) volume is a critical tool for the selection of patients who will undergo major
hepatic resection If the future liver remnant is of inadequate volume, preoperative portal
vein embolization can be used to induce hypertrophy of the future liver remnant to allow
safe resection. Liver tumors are deemed resectable if preoperative evaluation shows that
complete resection of the tumor-bearing liver leaves an adequate remnant volume with ade‐
quate vascular inflow, outflow, and biliary drainage. The treatment of each individual tu‐
mor type requires expertise in staging, systemic therapy, and hepatic surgery. [43, 45]
4.1.2. Nonresectional treatment
Percutaneous and intraoperative ablative techniques may play a role in the treatment of
many types of liver tumors because the therapy
1. can be performed percutaneously or with minimally invasive approaches,
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2. is associated with low morbidity and mortality, and
3. can help preserve liver parenchyma in selected patients.
The role of nonresectional ablative approaches for NCNNLM is not well defined. Data and
experience are still accruing, and for now such treatment should be considered only in those
centers that can provide the full spectrum of therapies for liver metastases. [43]
4.1.3. Hepatic arterial therapies
The utility of hepatic arterial therapies in the treatment of NCNNLM is not well understood.
TACE, TAE, and hepatic artery infusion are not considered standard therapy for NCNNLM.
For certain tumor subtypes, including unresectable soft tissue sarcomas (STS) and gastroin‐
testinal stromal tumors (GIST), these approaches hold promise. [43, 45]
4.2. Specific tumor types
4.2.1. Gastrointestinal tumors
Overall reported survival rates for patients with NCNNLM from gastrointestinal tumors
(esophageal, stomach, duodenum, pancreas, and small bowel) are worse than for those with
nongastrointestinal LM.
4.2.1.1. Esophagus and stomach
Currently, there are no accepted indications for resection of esophageal cancer LM, either for
palliation or cure. The justification for resection of gastric cancer liver metastases remains
controversial. A few published series from Japan and Korea, where the incidence of gastric
cancer is high, specifically address gastric cancer LM. Currently, hepatic resection for gastric
adenocarcinoma cannot be recommended as standard of care. Data supporting hepatic re‐
section in highly selected patients need confirmation by additional clinical studies. [43]
4.2.1.2. Small bowel
Metastases from small bowel adenocarcinoma are most often widespread and associated
with a dismal outcome regardless of treatment. There currently are no data to support resec‐
tion of small bowel LM except in highly selected cases. [43]
4.2.1.3. Anus
Liver metastases from anal adenocarcinoma are very uncommon, and a meaningful discus‐
sion of the indications for resection is difficult. [43]
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4.2.2. Bile ducts and pancreas
4.2.2.1. Gallbladder, hilar bile ducts, and ampulla
There currently are no generally accepted indications for hepatic resection in patients with
gallbladder cancer, cholangiocarcinoma, or ampullary carcinoma. Judicious recommenda‐
tions should be made on a case-by-case basis. [43, 45]
4.2.2.2. Pancreas
Even for pancreatic carcinoma patients without LM, the overall survival is poor. LM from
pancreatic adenocarcinoma occurs nearly always in the setting of disseminated systemic dis‐
ease.. In the majority of cases, benefit cannot be expected from hepatic resection for this dis‐
ease. [43, 45]
4.2.3. Breast
Although it has not been formally proven that liver resection prolongs survival for selected
patients with liver metastases of breast cancer, recent studies suggest that with careful pa‐
tient selection, resection of breast LM can produce long-term survival. Some authors also
suggest that patients first should undergo systemic chemotherapy, and that only patients
who do not progress should undergo liver resection. [45]
4.2.4. Genitourinary
4.2.4.1. Kidney
In patients with hepatic metastases of renal tumors in whom a complete resection seems
possible, surgical exploration may be justified. The number of studies evaluating renal tu‐
mors including Wilms' tumors, renal cell adenocarcinomas, and nephroblastomas are few,
and the cohorts of patients are small. [43, 45]
4.2.4.2. Testicle
Effective chemotherapeutic regimens are available for most reproductive tumors. Treatment
with chemotherapy can lead to complete responses. Surgical resection is considered a neces‐
sary salvage treatment in the absence of complete radiographic response to systemic thera‐
py, because residual teratomas have been known to degenerate into invasive carcinoma. [43]
“Salvage” hepatic resection may be considered because
1. resection is the only way to confirm a complete response in the residual liver masses,
2. teratomas may progress to malignant transformation in 30% of cases,
3. mortality and morbidity from hepatic resection is low, and
4. if feasible, concomitant resection of liver metastases and residual retroperitoneal dis‐
ease is associated with favorable outcome.
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Because of the small number of published cases, however, no general conclusions can be
drawn.
4.2.4.3. Uterus and ovary
The concept of hepatic resection for LM from ovarian cancer has evolved from the fact that cy‐
toreductive surgery can significantly alter the natural history of ovarian cancer metastatic to
the peritoneum. Resection of ovarian LM may be considered in carefully selected patients that
are candidates for complete cytoreduction after evaluation by a multidisciplinary team. [43]
4.2.5. Melanoma
Most patients with liver metastases of melanoma have unresectable disease owing to extra‐
hepatic disease or disseminated hepatic metastases. Isolated liver metastasis from cutaneous
melanoma is uncommon. Uveal melanoma is a distinct entity that seems to have a different
tumor biology, and it commonly spreads to the liver.. Hepatic resection has been performed
in both populations, although outcomes differ based on the primary site of origin. Hepatic
resection for uveal or cutaneous melanoma should only be considered in a multidisciplinary
setting and by experienced hepatic surgeons. [43, 45]
4.2.6. Adrenal
Hepatic resection can provide acceptable results in selected patients with limited adrenal
metastases, particularly for palliation of symptoms in patients with secreting hepatic tu‐
mors. For patients with symptomatic disease who are not candidates for surgery, ablative
therapy such as RFA may be an effective alternative therapy for symptom control. [43]
4.2.7. Soft tissue sarcoma and gastrointestinal stromal tumor
Hepatic resection for STS metastases is indicated for disease confined to the liver. Patients with
retroperitoneal and intra-abdominal visceral STS and those with leiomyosarcomas are more
likely to have liver-only metastatic disease than are patients with extra-abdominal STS.
The treatment strategy for patients with liver metastases from gastrointestinal stromal tumors
has changed since the development of the targeted agent imatinib mesylate, which achieves
dramatic tumor response rates. Imatinib is now the first-line treatment. Therapy with imatinib
has revolutionized the treatment of patients with GIST and has been used alone and in con‐
junction with hepatic resection for GIST LM. “Complete” radiographic response assessed by
CT or PET, including cystic changes after imatinib treatment of GIST, are not necessarily equiv‐
alent to complete pathologic response. Because hepatic lesions contain viable tumor in >85% of
cases after chemotherapy and biologic therapy, the goal of surgical treatment is complete re‐
moval of all residual disease including small residual cystic lesions and “scars.” [43, 45]
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4.2.8. Squamous cell carcinoma
Because the dataset is so heterogeneous, standard recommendations cannot be made, except
that careful patient selection for hepatic resection is mandatory. [43]
4.2.9. Lung cancer
Resection of liver metastases of lung cancer has been reported, and in selected patients long-
term survival has been achieved. [43]
4.2.10. Unknown primary cancer
Patients presenting with liver metastases from an unknown primary tumor are a challenge to
manage because median overall survival is approximately 5 months. The treatment plan for
these patients should be individualized and discussed in a multidisciplinary team. [43, 45]
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